Orlando, Florida, Wednesday, March 2, 2004 – The results of a clinical trial investigating the effects of Jarrow Formulas’ L-Arginine (L-arg) were presented by Dr. Shiela West of the University of Pennsylvania at the annual American Heart Association meeting held November 9-12, 2003 in Orlando, FL.
L-Arginine is the precursor for the potent vasodilator nitric oxide, and a growing body of research shows that L-arg lowers blood pressure (BP) and total peripheral vascular resistance (TPR).
Dr. West’s team measured the effects of short-term, oral L-arg supplements (12 g/d for 3 weeks) on systemic hemodynamics in 16 hypercholesterolemic men with normal BP. In this randomized, double-blind, two-period crossover design, L-arg tablets (1 g each) and matched placebos (microcrystalline cellulose) were provided by Jarrow Formulas.
Following each supplement period, hemodynamic measures were collected via impedance cardiography during a 30-minute baseline rest period at rest and during 2 behavioral stressor tasks (a brief public speaking task and the foot cold pressor, separated by a 20 min recovery period). Compared to levels collected during placebo, L-arg significantly reduced systolic BP (- 3.1 mmHg, p
In conclusion, 12g L-arg supplementation significantly lowered blood pressure and Hcy levels during a three-week period. “This study is the first to examine systemic hemodynamic effects of oral L-Arginine and the first to report reductions in homocysteine with oral L-Arginine,” said Sid Shastri, Vice President, Product Development at Jarrow Formulas. “Lower homocysteine may be one of many mechanisms, including modulation of endothelial nitric oxide, for the well-documented cardiovascular effects of L-Arginine.”
For more technical information, contact Sid Shastri, Vice President, Product Development or for all other inquiries Mark Becker, Director, Advertising/Communications toll free at (800) 726-0886 or access the Jarrow Formulas Web site at www.Jarrow.com.